The company's Direct-to-Patient offering now encompasses Clinical Site-to-Patient, Pharmacy-to-Patient, and Depot-to-Patient services, according to Thermo Fisher Scientific. The program can support any phase of a clinical trial, as well as a range of trial variables including interactive response technology systems, blinded/unblinded studies, and home nursing providers.

Thermo Fisher's Q3 earnings boosted by COVID-19 sales
Products related to the novel coronavirus are spelling success for Thermo Fisher, which reported that revenue was up by 36% in the third quarter to $8.52 billion,...

Thermo Fisher launches closed cell processing system
Thermo Fisher Scientific has launched the Gibco CTS Rotea counterflow centrifugation system, a modular, closed cell therapy processing system for cell...

Thermo Fisher debuts clinical research grant program
Thermo Fisher Scientific introduced a clinical research grant program to support health projects in oncology and reproductive health.

Thermo Fisher expands plastics production to support COVID-19 efforts
Thermo Fisher Scientific is investing an additional $140 million to further expand its laboratory plastics consumables production to support the...

Thermo Fisher center forms partnerships for biomarkers
Thermo Fisher Scientific announced new collaborations for clinical biomarker discovery among the Thermo Fisher Precision Medicine Science Center, AstraZeneca,...